1. Home
  2. AMTX vs AGEN Comparison

AMTX vs AGEN Comparison

Compare AMTX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMTX
  • AGEN
  • Stock Information
  • Founded
  • AMTX 2005
  • AGEN 1994
  • Country
  • AMTX United States
  • AGEN United States
  • Employees
  • AMTX N/A
  • AGEN N/A
  • Industry
  • AMTX Major Chemicals
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AMTX Industrials
  • AGEN Health Care
  • Exchange
  • AMTX Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • AMTX 96.3M
  • AGEN 87.7M
  • IPO Year
  • AMTX N/A
  • AGEN 2000
  • Fundamental
  • Price
  • AMTX $2.19
  • AGEN $4.80
  • Analyst Decision
  • AMTX Strong Buy
  • AGEN Buy
  • Analyst Count
  • AMTX 4
  • AGEN 4
  • Target Price
  • AMTX $13.43
  • AGEN $13.00
  • AVG Volume (30 Days)
  • AMTX 934.3K
  • AGEN 1.6M
  • Earning Date
  • AMTX 07-31-2025
  • AGEN 08-07-2025
  • Dividend Yield
  • AMTX N/A
  • AGEN N/A
  • EPS Growth
  • AMTX N/A
  • AGEN N/A
  • EPS
  • AMTX N/A
  • AGEN N/A
  • Revenue
  • AMTX $237,892,000.00
  • AGEN $99,524,000.00
  • Revenue This Year
  • AMTX $27.78
  • AGEN $12.69
  • Revenue Next Year
  • AMTX $91.59
  • AGEN N/A
  • P/E Ratio
  • AMTX N/A
  • AGEN N/A
  • Revenue Growth
  • AMTX N/A
  • AGEN N/A
  • 52 Week Low
  • AMTX $1.22
  • AGEN $1.38
  • 52 Week High
  • AMTX $4.73
  • AGEN $18.74
  • Technical
  • Relative Strength Index (RSI)
  • AMTX 65.90
  • AGEN 54.50
  • Support Level
  • AMTX $2.11
  • AGEN $4.38
  • Resistance Level
  • AMTX $2.39
  • AGEN $5.20
  • Average True Range (ATR)
  • AMTX 0.14
  • AGEN 0.57
  • MACD
  • AMTX 0.03
  • AGEN -0.10
  • Stochastic Oscillator
  • AMTX 66.03
  • AGEN 43.60

About AMTX Aemetis Inc. (DE)

Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: